Actively Recruiting
Evaluating Oral Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma A Phase I Dose-Escalation Trial
Led by National Cancer Institute (NCI) · Updated on 2026-10-21
30
Participants Needed
43
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and best dose of the drug triapine combined with radiation therapy in adults with recurrent glioblastoma or astrocytoma. These tumors have returned after a period of improvement. Triapine may block enzymes needed for tumor growth, and radiation therapy uses high-energy rays to kill cancer cells. The study aims to find the safest dose and observe how this combination affects tumor control and patient outcomes. Participants receive intensity-modulated radiation therapy IMRT once daily, five days a week, for two weeks totaling 10 treatment days. Oral triapine is taken two hours before each radiation session, provided there is no disease progression or unacceptable side effects. During the study, patients undergo CT andor MRI scans, blood tests, and potentially cerebrospinal fluid collection during screening. After treatment, patients are followed for up to five years with regular check-ups. During the trial, participants are closely monitored for side effects and response to treatment using imaging and blood tests. The main measurement is the occurrence of dose-limiting toxicities within 28 days. Secondary outcomes include tumor response, survival times, and the need for additional symptom control medications. The study also examines how genetic mutations relate to treatment outcomes. Follow-up visits occur two weeks after radiation and then every three months for up to five years.
CONDITIONS
Brief Title
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here